Effects of adenosine A 2A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Warren, Cirle A ^a   Calabrese, Gina M ^a   Li, Yuesheng ^a   Pawlowski, Sean W ^a   Figler, Robert A ^a,d   Rieger, Jayson ^d   Ernst, Peter B ^c   Linden, Joel ^b,d   Guerrant, Richard L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Dogwood Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ALANYLGLUTAMINE; ATL 370; CLOSTRIDIUM DIFFICILE TOXIN A; CXCL1 CHEMOKINE; INTERLEUKIN 10; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; BACTERIAL TOXIN; DIPEPTIDE; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HISTOPATHOLOGY; ILEITIS; ILEUM MUCOSA; INTESTINE SECRETION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN LOCALIZATION; RAT; TREATMENT RESPONSE; TYPHLITIS; ANIMAL; C57BL MOUSE; CLOSTRIDIUM DIFFICILE; CYTOCHEMISTRY; DISEASE MODEL; MOUSE; PATHOGENICITY; PATHOLOGY; RABBIT; TREATMENT OUTCOME;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENTEROTOXINS; HISTOCYTOCHEMISTRY; ILEITIS; MALE; MICE; MICE, INBRED C57BL; RABBITS; TREATMENT OUTCOME; TYPHLITIS;

EID: 84862826280     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-13     Document Type: Article

References (49)

1. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280. 10.1086/502539, 15796280.
2. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472. 10.1503/cmaj.1041104, 514643, 15337727.
3. McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441. 10.1056/NEJMoa051590, 16322603.
4. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992, 117:297-302.
5. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008, 5:40-48. 10.1038/ncpgasthep1029, 18174906.
6. Carneiro-Filho BA, Bushen OY, Brito GA, Lima AA, Guerrant RL. Glutamine Analogues As Adjunctive Therapy for Infectious Diarrhea. Curr Infect Dis Rep 2003, 5:114-119. 10.1007/s11908-003-0046-2, 12641996.
7. Curi R, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC. Glutamine-dependent changes in gene expression and protein activity. Cell Biochem Funct 2005, 23:77-84. 10.1002/cbf.1165, 15386529.
8. Rhoads JM, Argenzio RA, Chen W, Rippe RA, Westwick JK, Cox AD, Berschneider HM, Brenner DA. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am J Physiol 1997, 272:G943-G953.
9. Chang WK, Yang KD, Chuang H, Jan JT, Shaio MF. Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Clin Immunol 2002, 104:151-160. 10.1006/clim.2002.5257, 12165276.
10. Wischmeyer PE, Musch MW, Madonna MB, Thisted R, Chang EB. Glutamine protects intestinal epithelial cells: role of inducible HSP70. Am J Physiol 1997, 272:G879-G884.
11. Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis 2002, 186:1438-1447. 10.1086/344729, 12404159.
12. Carneiro BA, Fujii J, Brito GA, Alcantara C, Oria RB, Lima AA, Obrig T, Guerrant RL. Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro. Infect Immun 2006, 74:81-87. 10.1128/IAI.74.1.81-87.2006, 1346681, 16368960.
13. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5-13.
14. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol 2001, 132:1017-1026. 10.1038/sj.bjp.0703893, 1572638, 11226132.
15. Cavalcante IC, Castro MV, Barreto AR, Sullivan GW, Vale M, Almeida PR, Linden J, Rieger JM, Cunha FQ, Guerrant RL, et al. Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun 2006, 74:2606-2612. 10.1128/IAI.74.5.2606-2612.2006, 1459724, 16622196.
16. Alcantara C, Stenson WF, Steiner TS, Guerrant RL. Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J Infect Dis 2001, 184:648-652. 10.1086/322799, 11474431.
17. Alcantara CS, Jin XH, Brito GA, Carneiro-Filho BA, Barrett LJ, Carey RM, Guerrant RL. Angiotensin II subtype 1 receptor blockade inhibits Clostridium difficile toxin A-induced intestinal secretion in a rabbit model. J Infect Dis 2005, 191:2090-2096. 10.1086/430316, 15897995.
18. Pawlowski SW, Calabrese G, Kolling GL, Freire R, Alcantara Warren C, Liu B, Sartor B, Guerrant RL. Murine model of Clostridium difficile infection using gnotobiotic aged C57Bl/6 mice and a BI strain. J Infect Dis 2010, 202:1708-1712. 10.1086/657086, 3057484, 20977342.
19. Pierce BCA Protein Assay Kit. , http://www.piercenet.com/instructions/2161296.pdf
20. Quantikine® Mouse CXCL1/KC Immunoassay. , http://www.rndsystems.com/pdf/mkc00b.pdf
21. Quantikine® Mouse IL-10 Immunoassay. , http://www.rndsystems.com/pdf/m1000.pdf
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.
23. Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 1988, 56:582-588. 259330, 3343050.
24. Pothoulakis C, Lamont JT. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001, 280:G178-G183.
25. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18:247-263. 10.1128/CMR.18.2.247-263.2005, 1082799, 15831824.
26. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-3. 10.1038/nature09397, 20844489.
27. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-9. 10.1038/nature07822, 2679968, 19252482.
28. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985, 47:349-52. 263173, 3917975.
29. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001, 53:527-552.
30. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 2005, 129:26-33. 10.1053/j.gastro.2005.05.032, 16012931.
31. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996, 270:C522-C529.
32. Blachier F, Boutry C, Bos C, Tome D. Metabolism and functions of L-glutamate in the epithelial cells of the small and large intestines. Am J Clin Nutr 2009, 90:814S-821S. 10.3945/ajcn.2009.27462S, 19571215.
33. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid?. Nutr Rev 1990, 48:297-309.
34. Papaconstantinou HT, Hwang KO, Rajaraman S, Hellmich MR, Townsend CM, Ko TC. Glutamine deprivation induces apoptosis in intestinal epithelial cells. Surgery 1998, 124:152-159. 10.1016/S0039-6060(98)70115-1, 9706133.
35. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB. Glutamine reduces cytokine release, organ damage, and mortality in a rat model of endotoxemia. Shock 2001, 16:398-402. 10.1097/00024382-200116050-00014, 11699081.
36. Ban K, Kozar RA. Enteral glutamine: a novel mediator of PPARgamma in the postischemic gut. J Leukoc Biol 2008, 84:595-599. 10.1189/jlb.1107764, 2516899, 18390929.
37. Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol Rev 1997, 49:381-402.
38. Strohmeier GR, Reppert SM, Lencer WI, Madara JL. The A2b adenosine receptor mediates cAMP responses to adenosine receptor agonists in human intestinal epithelia. J Biol Chem 1995, 270:2387-2394. 10.1074/jbc.270.5.2387, 7836474.
39. Hasko G, Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J Leukoc Biol 2008, 83:447-455. 2268631, 18160539.
40. Moore CC, Martin EN, Lee GH, Obrig T, Linden J, Scheld WM. An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis 2008, 8:141. 10.1186/1471-2334-8-141, 2588444, 18937852.
41. Sullivan GW, Fang G, Linden J, Scheld WM. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 2004, 189:1897-1904. 10.1086/386311, 15122527.
42. Bai MX, Jiang ZM, Liu YW, Wang WT, Li DM, Wilmore DW. Effects of alanyl-glutamine on gut barrier function. Nutrition 1996, 12:793-796. 10.1016/S0899-9007(96)00217-1, 8974106.
43. Braga-Neto MB, Warren CA, Oria RB, Monteiro MS, Maciel AA, Brito GA, Lima AA, Guerrant RL. Alanyl-glutamine and glutamine supplementation improves 5-fluorouracil-induced intestinal epithelium damage in vitro. Dig Dis Sci 2008, 53:2687-2696. 10.1007/s10620-008-0215-0, 18320312.
44. Lima AA, Carvalho GH, Figueiredo AA, Gifoni AR, Soares AM, Silva EA, Guerrant RL. Effects of an alanyl-glutamine-based oral rehydration and nutrition therapy solution on electrolyte and water absorption in a rat model of secretory diarrhea induced by cholera toxin. Nutrition 2002, 18:458-462. 10.1016/S0899-9007(02)00775-X, 12044816.
45. Scheppach W, Loges C, Bartram P, Christl SU, Richter F, Dusel G, Stehle P, Fuerst P, Kasper H. Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon. Gastroenterology 1994, 107:429-434.
46. Carneiro-Filho BA, Oria RB, Wood RK, Brito GA, Fujii J, Obrig T, Lima AA, Guerrant RL. Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 2004, 20:934-941. 10.1016/j.nut.2004.06.016, 15474885.
47. Saito H, Terada T, Shimakura J, Katsura T, Inui K. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1). Am J Physiol Gastrointest Liver Physiol 2008, 295:G395-G402. 10.1152/ajpgi.90317.2008, 18583459.
48. Schiller CM, Huang TI, Heizer WD. Isolation and characterization of four peptide hydrolases from the cytosol of rat intestinal mucosa. Gastroenterology 1977, 72:93-100.
49. Bloom PD, Boedeker EC. Mucosal immune responses to intestinal bacterial pathogens. Semin Gastrointest Dis 1996, 7:151-166.